Presentation is loading. Please wait.

Presentation is loading. Please wait.

ESPN Lyon 2008 What can we expect from enzyme replacement on renal involvement ? L Dubourg Exploration fonctionnelle rénale et Unité de Néphrologie Pédiatrique.

Similar presentations


Presentation on theme: "ESPN Lyon 2008 What can we expect from enzyme replacement on renal involvement ? L Dubourg Exploration fonctionnelle rénale et Unité de Néphrologie Pédiatrique."— Presentation transcript:

1 ESPN Lyon 2008 What can we expect from enzyme replacement on renal involvement ? L Dubourg Exploration fonctionnelle rénale et Unité de Néphrologie Pédiatrique Hôpital E Herriot et Université Claude Bernard - INSERM U Lyon

2 Fabry disease X-linked inherited lysosomal storage disorder deficiency of -galactosidase A progressive accumulation of globotriaosylceramide (Gb 3 )

3 Fabry disease Accumulation in many types of cells nervous system skin heart kidney vascular endothelial cells gastro- intestinal symptoms pain skin early symtoms brainheartkidney late symtoms

4 Renal involvement in Fabry disease Tondel et al., Am J Kidney Disease, 2008

5 Renal involvement in Fabry disease Thurberg et al., kidney int 2002

6 Organ–specific disease progression Breuning et al., J Nephrol, 2008

7 Renal involvement in Fabry disease Branton et al., Medicine, 2002

8 Germain et al., J Am Soc Nephrol 2007 Enzyme replacement therapy (ERT) double-blind placebo controlled period 54 months 58 patients (56 males) mean age 31.1 years Pcr 71 ± 17.7 µmol/l

9 Thurberg et al. kidney int 2002 Germain et al., J Am Soc Nephrol 2007 ERT

10 Thurberg et al. kidney int 2002 Germain et al., J Am Soc Nephrol 2007 ERT

11 Thurberg et al. kidney int 2002 Germain et al., J Am Soc Nephrol 2007 ERT

12 Thurberg et al. kidney int 2002 Germain et al., J Am Soc Nephrol 2007 ERT

13 Enzyme replacement therapy (ERT) eGFR Germain et al., J Am Soc Nephrol 2007

14 Enzyme replacement therapy (ERT) Germain et al., J Am Soc Nephrol 2007

15 Enzyme replacement therapy 25 patients 21 males : 31.1 ± 2.7 years 4 females : 35.2 ± 8.3 years Time from start of -Gal treatment (years) inulin clearance (ml/min/1.73 m 2 ) < > 30 alb/creat (mg/mmol) (n = 6) (n = 9) (n = 10) mean decline in GFR (ml/min/1.73 per year) -0.8 ± ± ± 0.9

16 ERT Banikazemi et al., Ann Intern Med, 2007 double-blind placebo controlled median : 18.5 months 82 patients mean age 45 years Pcr 141 ± 44 µmol/l

17 Branton et al., Medecine, 2002 Fabry disease : onset of symptoms

18 Fabry disease Tondel et al., Am J Kidney Disease, 2008

19 ERT in children Ries et al., Pediatrics, 2006 Ramaswami et al., Acta Paediatrica, 2007 Wraith et al., J Pediatr, 2008 results safety normalisation of Gb 3 plasma concentration decrease in pain and gastro-intestinal symptoms improvement of autonomic function decrease in micro-albuminuria

20 Brenner et al., Curr Opin Nephrol Hypertens, 2004 What can we expect from enzyme replacement on renal involvement ?

21 Acknowledgments Département des Maladies Héréditaires du Métabolisme Exploration Fonctionnelle rénale et métabolique Département de Néphrologie Pédiatrique

22


Download ppt "ESPN Lyon 2008 What can we expect from enzyme replacement on renal involvement ? L Dubourg Exploration fonctionnelle rénale et Unité de Néphrologie Pédiatrique."

Similar presentations


Ads by Google